BaroneR, Borson-ChazotF, ValkemaRet al.Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: Relevance of kidney volume and dose rate in finding a dose–effect relationship. J Nucl Med, 2005; 46,suppl:99S.
2.
BodeiL, CremonesiM, FerrariMet al.Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: The role of associated risk factors. Eur J Nucl Med Mol Imaging, 2008; 35:1847.
3.
O'DonoghueJ. Relevance of external beam dose-response relationships to kidney toxicity associated with radionuclide therapy. Cancer Biother Radiopharm, 2004; 19:378.
BouchetLG, BolchWE, BlancoHPet al.MIRD Pamphlet No. 19: Absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. J Nucl Med, 2003; 44:1113.
6.
WesselsBW, KonijnenbergMW, DaleRGet al.MIRD Pamphlet No. 20: The effect of model assumptions on kidney dosimetry and response—implications for radionuclide therapy. J Nucl Med, 2008; 49:1884.
7.
de JongM, ValkemaR, van GamerenAet al.Inhomogeneous localization of radioactivity in the human kidney after injection of [111In-DTPA]octreotide. J Nucl Med, 2004; 45:1168.
8.
FreireichEJ, GehanEA, RailDet al.Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep, 1966; 50:219–244.
9.
Reagan-ShawS, NihalM. Ahmad N Dose translation from animal to human studies revisited. FASEB J, 2008; 22:659.
10.
DeNardoGL, YuanA, GoldsteinDet al.Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs. Cancer Biother Radiopharm, 2003; 18:2312003.
11.
CremonesiM, FerrariM, BodeiLet al.Dosimetry in peptide receptor therapy: A review. J Nucl Med, 2006; 47:1467.
12.
KonijnenbergMW. Is the renal dosimetry for [90Y-DOTA, Tyr3]octreotide accurate enough to predict thresholds for individual patients?Cancer Biother Radiopharm, 2003; 18:619.
13.
DeNardoGL, DeNardoSJ, BalhornR. Systemic radiotherapy can cure lymphoma: A paradigm for other malignancies?Cancer Biother Radiopharm, 2008; 23:383.
